The importance of total kidney volume in evaluating progression of polycystic kidney disease

The rate at which autosomal dominant polycystic kidney disease (ADPKD) progresses to end-stage renal disease varies widely and is determined by genetic and non-genetic factors. The ability to determine the prognosis of children and young adults with ADPKD is important for the effective life-long management of the disease and to enable the efficacy of emerging therapies to be determined. Total kidney volume (TKV) reflects the sum volume of hundreds of individual cysts with potentially devastating effects on renal function. The sequential measurement of TKV has been advanced as a dynamic biomarker of disease progression, yet doubt remains among nephrologists and regulatory agencies as to its usefulness. Here, we review the mechanisms that lead to an increase in TKV in ADPKD, and examine the evidence supporting the conclusion that TKV provides a metric of disease progression that can be used to assess the efficacy of potential therapeutic regimens in children and adults with ADPKD. Moreover, we propose that TKV can be used to monitor treatment efficacy in patients with normal levels of renal function, before the pathologic processes of ADPKD cause extensive fibrosis and irreversible loss of functioning renal tissue.

[1]  M. Bunni,et al.  Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease , 2015, Physiological reports.

[2]  Douglas Landsittel,et al.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[3]  J. Grantham.  Rationale for early treatment of polycystic kidney disease , 2015, Pediatric Nephrology.

[4]  Kaleab Z. Abebe,et al.  Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  G. Walz,et al.  Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.

[6]  L. Cantley,et al.  Macrophages promote cyst growth in polycystic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[7]  J. Bonventre.  Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  A. Evan,et al.  Cyst formation and growth in autosomal dominant polycystic kidney disease. , 1987, Kidney international.

[9]  E. J. van der Jagt,et al.  Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  V. Mai,et al.  Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury , 2006, Pediatric Nephrology.

[11]  Kaleab Z. Abebe,et al.  Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[12]  O. Dalgaard.  Bilateral polycystic disease of the kidneys; a follow-up of 284 patients and their families. , 1957, Danish medical bulletin.

[13]  R. Gansevoort,et al.  Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  V. Tesar,et al.  Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. , 2003, Physiological research.

[15]  A. Evan,et al.  Renal cystic disease induced by diphenylthiazole. , 1983, Kidney international.

[16]  P. Gabow,et al.  Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. , 1984, Annals of internal medicine.

[17]  R. Schrier,et al.  Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[18]  Yanhong Wu,et al.  Vasopressin directly regulates cyst growth in polycystic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[19]  J. Felmlee,et al.  Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[20]  J. Grantham,et al.  Acquired cystic kidney disease. , 1991, Kidney international.

[21]  B F King,et al.  Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. , 2000, Journal of the American Society of Nephrology : JASN.

[22]  Vincent H Gattone,et al.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.

[23]  Kaleab Z. Abebe,et al.  Blood pressure in early autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.

[24]  L H Wetzel,et al.  Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. , 2000, Kidney international.

[25]  D. Wallace,et al.  J Am Soc Nephrol 14: 2588–2595, 2003 Urinary Excretion of Monocyte Chemoattractant Protein-1 in Autosomal Dominant Polycystic Kidney Disease , 2022 .

[26]  K. Bae,et al.  Evidence of extraordinary growth in the progressive enlargement of renal cysts. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[27]  F. Cosio,et al.  Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[28]  J. D. de Fijter,et al.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  O. Dalgaard.  BILATERAL POLYCYSTIC DISEASE OF THE KIDNEYS , 1959 .

[30]  P. Harris,et al.  A polycystin-centric view of cyst formation and disease: the polycystins revisited , 2015, Kidney international.

[31]  W. P. Reed,et al.  Accelerated renal cyst development in deconditioned germ-free rats. , 1986, Kidney international.

[32]  F. Carone,et al.  Tubular cell and matrix changes in renal cystic disease. , 1993, Contributions to Nephrology.

[33]  R. Gansevoort,et al.  Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. , 2016, Nephrology, Dialysis and Transplantation.

[34]  T. Mochizuki,et al.  Renal disease progression in autosomal dominant polycystic kidney disease , 2012, Clinical and Experimental Nephrology.

[35]  V. Torres,et al.  Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities , 2007, Journal of internal medicine.

[36]  Bradley J Erickson,et al.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.

[37]  D. Wallace.  Cyclic AMP-mediated cyst expansion. , 2011, Biochimica et biophysica acta.

[38]  W. P. Reed,et al.  Endotoxin provocation of experimental renal cystic disease. , 1987, Kidney international.

[39]  M. Chonchol,et al.  Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  V. Torres,et al.  Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy , 2012, Nature Reviews Nephrology.

[41]  L. Onuchic,et al.  Renal cyst growth is the main determinant for hypertension and concentrating deficit in PKD1-deficient mice , 2014, Kidney international.

[42]  N. Bricker.  On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". , 1974, The New England journal of medicine.

[43]  Luca Antiga,et al.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial , 2013, The Lancet.

[44]  F. Epstein,et al.  Functional correlates of compensatory renal hypertrophy. , 1968, The Journal of clinical investigation.

[45]  V. Torres,et al.  Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease , 2013, Current opinion in nephrology and hypertension.

[46]  R. Maser,et al.  Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. , 2003, Kidney international.

[47]  P. Azurmendi,et al.  Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  F. Reubi,et al.  Rate of functional deterioration in polycystic kidney disease. , 1983, Kidney international.

[49]  W. Weimar,et al.  Long-term consequences of kidney donation. , 2009, The New England journal of medicine.

[50]  M. Klein,et al.  Volume Progression in Polycystic Kidney Disease , 2007 .

[51]  D. Bichet.  A defect in vasopressin secretion in autosomal dominant polycystic kidney disease. , 2012, Kidney international.

[52]  R. Gansevoort,et al.  Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[53]  Oliver Senn,et al.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. , 2010, The New England journal of medicine.

[54]  J. Grantham,et al.  Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.

[55]  Berenice Y. Gitomer,et al.  Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[56]  K. Bae,et al.  Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study , 2013, PloS one.

[57]  E. J. van der Jagt,et al.  Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[58]  Satoru Muto,et al.  The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease , 2011, Clinical and Experimental Nephrology.

[59]  R. Schrier,et al.  Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. , 2008, Kidney international.

[60]  C. Mei,et al.  Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation. , 2013, Molecular medicine reports.

[61]  Dalgaard Oz.  Bilateral polycystic disease of the kidneys; a follow-up of 284 patients and their families. , 1957 .

[62]  D. Wallace,et al.  Macrophages promote polycystic kidney disease progression , 2013, Kidney international.

[63]  T. Seeman,et al.  Blood pressure and renal function in autosomal dominant polycystic kidney disease , 1997, Pediatric Nephrology.

[64]  A. Chapman,et al.  Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[65]  R. Wüthrich,et al.  Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease , 2014, PloS one.

[66]  V. Torres,et al.  Autosomal dominant polycystic kidney disease: the last 3 years. , 2009, Kidney international.

[67]  K. Bae,et al.  A comparison of ultrasound and magnetic resonance imaging shows kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease , 2015, Kidney international.

[68]  Luca Antiga,et al.  Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[69]  L T Cook,et al.  Determinants of renal volume in autosomal-dominant polycystic kidney disease. , 2008, Kidney international.

[70]  R. Gansevoort,et al.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[71]  J. Stockman,et al.  Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease , 2012 .

[72]  H. Thomsen,et al.  Volume of polycystic kidneys during reduction of renal function , 1981, Urologic radiology.

[73]  Kaleab Z. Abebe,et al.  Bioactive lipid mediators in polycystic kidney disease , 2014, Journal of Lipid Research.

[74]  A. Paterson,et al.  Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[75]  T. Ecder.  Cardiovascular complications in autosomal dominant polycystic kidney disease. , 2013, Current hypertension reviews.

[76]  R. Maser,et al.  Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease. , 2014, The American journal of pathology.

[77]  J. Grantham,et al.  The role of computed tomography in the evaluation of adult polycystic kidney disease. , 1981, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  L. Antiga,et al.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.

[79]  R. Schrier,et al.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.